谷歌母公司Alphabet联合创始人哈萨比斯领导的AI药物研发公司Isomorphic Labs完成21亿美元B轮融资，由Thrive Capital领投，Alphabet及多国主权基金参投。资金将用于推动AI发现的候选药物进入临床试验。该公司2021年成立于伦敦，专注用AI重构药物发现流程，此次融资创下领域纪录，凸显资本对AI制药前景的信心。
OpenAI CEO 萨姆・奥尔特曼近日表示，公司正考虑投资或补贴那些大量应用其AI技术进行新药研发的公司。此举旨在推动医疗科研发展，并可能为OpenAI带来丰厚回报。奥尔特曼指出，随着AI在科学探索中的作用日益重要，制药行业亟需资金支持前沿科研。
OpenAI正探索新商业模式，计划从客户利用其AI系统实现的研发成果中抽取分成。这一模式尚处内部讨论阶段，已引发科技、制药等领域关注。
初创公司Chai Discovery与礼来合作，利用其AI算法Chai-2加速抗体药物研发。公司创始人来自OpenAI，获CEO支持，展现AI与生物医药融合潜力。
Xai
$1.4
Input tokens/M
$3.5
Output tokens/M
2k
Context Length
Anthropic
$105
$525
200
Google
$0.7
$2.8
1k
$7
$35
$2.1
$17.5
$21
Alibaba
-
$6
$24
256
Baidu
128
Bytedance
$1.2
$3.6
4
$2
$3.9
$15.2
64
%20--%3e%3cdefs%3e%3cstyle%3e%20.st0%20{%20fill:%20%23061b40;%20}%20.st1%20{%20fill:%20%23306af1;%20}%20.st2%20{%20fill:%20%235ce5cf;%20}%20%3c/style%3e%3c/defs%3e%3cg%3e%3cpath%20class='st0'%20d='M55,10.5h9v3h-9v9h12V7.5h-12v3ZM64,19.5h-6v-3h6v3Z'/%3e%3cpolygon%20class='st0'%20points='69%2016.5%2078%2016.5%2078%2019.5%2069%2019.5%2069%2022.5%2081%2022.5%2081%2013.5%2072%2013.5%2072%2010.5%2081%2010.5%2081%207.5%2069%207.5%2069%2016.5'/%3e%3cpolygon%20class='st0'%20points='95%2010.5%2095%207.5%2083%207.5%2083%2022.5%2095%2022.5%2095%2019.5%2086%2019.5%2086%2016.5%2095%2016.5%2095%2013.5%2086%2013.5%2086%2010.5%2095%2010.5'/%3e%3cpath%20class='st0'%20d='M40,1.5v21h11.6l1.4-1.4v-7.6h0c0,0-1.4-1.5-1.4-1.5l1.4-1.4V2.9l-1.4-1.4h-11.6ZM50,19.5h-7v-6h7v6ZM50,10.5h-7v-6h7v6Z'/%3e%3c/g%3e%3cpath%20class='st1'%20d='M23.1,24L14.7,4.8l-4.9,11.2h3.8l-1.8,4H3.3L12.1,0H2C.9,0,0,.9,0,2v20c0,1.1.9,2,2,2h21.1Z'/%3e%3cpath%20class='st2'%20d='M34,0h-16.8l10.6,24h6.2c1.1,0,2-.9,2-2V2C36,.9,35.1,0,34,0ZM32.5,20h-4V4h4v16Z'/%3e%3c/svg%3e)
